{"type":"trials","record":{"id":28309,"source_id":"clinicaltrials-gov","external_id":"NCT03092492","title":"AMD Ryan Initiative Study (ARIS)","brief_summary":"Objective: To learn more about AMD. Eligibility: People ages 55 and older with any of the following: Early AMD RPD Healthy eyes Design: Participants will be screened with: Eye exam: The pupil will be dilated with eye drops. Eye pressure and movements will be checked. Pictures will be taken of the inside of the eye. Reading an eye chart. Optical coherence tomography (OCT): The eyes are dilated. A machine measures the thickness of the retina. Participants will have a first visit that includes: Repeat of screening procedures Medical history Physical exam Questions about vision and general health Dark adapted fundus perimetry: Participants sit in the dark for 40 minutes. Then they sit at a machine that shines lights in the eyes. Dark adaption testing: Participants sit in the dark for 45 minutes. The pupils are dilated. They push a button when they see light in a machine for up to 1 hour. Participants will have annual visits for up to 5 years to repeat the tests in the first visit. Participant data may be shared for other research....","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"National Eye Institute (NEI)","enrollment":26,"countries":["United States"],"start_date":"2018-02-12","completion_date":"2022-04-11","last_update_date":"2026-09-18","source_url":"https://clinicaltrials.gov/study/NCT03092492","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"55 Years to 120 Years","comparator":null,"organization":"National Institutes of Health Clinical Center (CC)","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Enroll participants with early AMD (medium size drusen) to assess rate of change in drusen volume and progression rates…","Better understand the natural history of RPD as well as to document structural and functional changes over time and ass…","Identify potential risk factors for disease progression and possible outcome variables for future studies — 5 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03092492","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-02-12 to 2022-04-11","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years to 120 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.793Z","intervention":[],"participants":26,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Enroll participants with early AMD (medium size drusen) to assess rate of change in drusen volume and progression rates…","Better understand the natural history of RPD as well as to document structural and functional changes over time and ass…","Identify potential risk factors for disease progression and possible outcome variables for future studies — 5 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28309","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}